Deborah Ann Miller Sells 14,300 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 14,300 shares of Nuvalent stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $110.16, for a total value of $1,575,288.00. Following the sale, the insider directly owned 59,634 shares in the company, valued at approximately $6,569,281.44. This trade represents a 19.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Deborah Ann Miller also recently made the following trade(s):

• On Wednesday, January 21st, Deborah Ann Miller sold 700 shares of Nuvalent stock. The shares were sold at an average price of $109.84, for a total value of $76,888.00.
• On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The stock was sold at an average price of $97.16, for a total value of $251,547.24.
• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total value of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The shares were sold at an average price of $103.16, for a total value of $2,248,888.00.

Nuvalent Price Performance

Shares of NUVL stock opened at $106.44 on Friday. Nuvalent, Inc. has a one year low of $55.53 and a one year high of $113.01. The stock has a fifty day moving average price of $105.12 and a 200 day moving average price of $91.16. The stock has a market cap of $7.74 billion, a P/E ratio of -20.01 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same quarter in the prior year, the business posted ($1.28) EPS. Equities research analysts anticipate that Nuvalent, Inc. will post -3.86 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after acquiring an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Nuvalent during the third quarter worth approximately $38,000. Eastern Bank bought a new stake in shares of Nuvalent during the third quarter valued at approximately $52,000. Persistent Asset Partners Ltd acquired a new stake in shares of Nuvalent in the second quarter valued at approximately $88,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Nuvalent by 9,230.8% in the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after purchasing an additional 1,200 shares in the last quarter. 97.26% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. HC Wainwright raised their price target on shares of Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Truist Financial set a $140.00 target price on Nuvalent in a research report on Monday, November 24th. Piper Sandler boosted their price target on Nuvalent from $112.00 to $128.00 and gave the company an “overweight” rating in a research note on Monday, October 27th. The Goldman Sachs Group increased their price objective on Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, UBS Group reissued a “buy” rating on shares of Nuvalent in a report on Wednesday, December 17th. Fifteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Nuvalent has a consensus rating of “Moderate Buy” and an average price target of $138.33.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.